These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30458933)

  • 21. Challenges to pharmaceutical policymaking: lessons from Australia's national medicines policy.
    Lipworth W; Doran E; Kerridge I; Day R
    Aust Health Rev; 2014 May; 38(2):160-8. PubMed ID: 24589424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Italy: health system review.
    Ferre F; de Belvis AG; Valerio L; Longhi S; Lazzari A; Fattore G; Ricciardi W; Maresso A
    Health Syst Transit; 2014; 16(4):1-168. PubMed ID: 25471543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [International reference prices and cost minimization analysis for the regulation of medicine prices in Colombia].
    Vacca C; Acosta A; Rodriguez I
    Value Health; 2011; 14(5 Suppl 1):S16-9. PubMed ID: 21839891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Citizens' views on prices of medicines reimbursed by the National Health Service: Findings from Italian online focus groups.
    Colombo C; Caldara D; Banzi R
    Health Expect; 2024 Apr; 27(2):e14005. PubMed ID: 38432872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug Policy in Latvia.
    Silins J; Szkultecka-Dębek M
    Value Health Reg Issues; 2017 Sep; 13():73-78. PubMed ID: 29073995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Italy's health system reforms on hold.
    Paterlini M
    Lancet; 2013 Mar; 381(9872):1085-6. PubMed ID: 23547295
    [No Abstract]   [Full Text] [Related]  

  • 27. Cultural shift in Italy's drug policy.
    Garattini S
    Lancet; 1995 Jul; 346(8966):5-6. PubMed ID: 7603156
    [No Abstract]   [Full Text] [Related]  

  • 28. The impact of pharmaceutical cost containment policies on the range of medicines available and subsidized in Finland and New Zealand.
    Aaltonen K; Ragupathy R; Tordoff J; Reith D; Norris P
    Value Health; 2010; 13(1):148-56. PubMed ID: 19744294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Working together for public health.
    Martelli P
    Transcult Psychiatry; 2009 Jun; 46(2):316-27. PubMed ID: 19541753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The cultural shift in Italy's pharmaceutical policy in 1994: a case history.
    Garattini S
    J Ambul Care Manage; 2004; 27(2):120-6. PubMed ID: 15069989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
    Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
    Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Access to medicines in the public sector: analysis of users of the Brazilian Unified National Health System].
    Boing AC; Bertoldi AD; Boing AF; Bastos JL; Peres KG
    Cad Saude Publica; 2013 Apr; 29(4):691-701. PubMed ID: 23568299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Health technology assessment in Italy.
    France G
    Int J Technol Assess Health Care; 2000; 16(2):459-74. PubMed ID: 10932419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Health care reforms in Italy: towards an health system with national rights and local responsibilities].
    Boccia A; De Giusti M; Del Cimmuto A; Tufi D; Villari P
    Ann Ig; 2003; 15(6):771-85. PubMed ID: 15049535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Supply chain management of health commodities for reducing global disease burden.
    Chukwu OA; Ezeanochikwa VN; Eya BE
    Res Social Adm Pharm; 2017; 13(4):871-874. PubMed ID: 27720436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A proposed analytical framework for qualitative evaluation of access to medicines from a health systems perspective.
    Joosse IR; van den Ham HA; Mantel-Teeuwisse AK; Suleman F
    BMC Res Notes; 2024 Jun; 17(1):159. PubMed ID: 38849915
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Balancing health and industrial policy objectives in the pharmaceutical sector: lessons from Australia.
    Morgan S; McMahon M; Greyson D
    Health Policy; 2008 Aug; 87(2):133-45. PubMed ID: 18295927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The essential of medical assistance and the rationalisation of the budgetary expediture].
    Schena FP
    G Ital Nefrol; 2002; 19(2):123-4. PubMed ID: 12195409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The public production of medicines compared to the National Policy of Medicines and the burden of disease in Brazil.
    Figueiredo TA; Schramm JMA; Pepe VLE
    Cad Saude Publica; 2017 Sep; 33(9):e00179815. PubMed ID: 28977283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nationwide survey of neonatal transportation practices in Italy.
    Gente M; Aufieri R; Agostino R; Fedeli T; Calevo MG; Massirio P; Bellini C;
    Ital J Pediatr; 2019 Apr; 45(1):51. PubMed ID: 30999944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.